Hematocrit determination. The hematocrit (Hct) was determined using an uncoated capillary tube and a HemataSTAT-II instrument. When necessary, autologous plasma was added or removed to adjust the Hct to the values indicated in the experiment.
Hemoximetry. 1 Hemoximetry was used to assess oxygen saturation in purified HbS/HbA or whole blood by generating oxygen equilibrium curves (OECs) which relate the extent of Hb-O 2 saturation to the partial pressure of O 2 (pO 2 ) and measure the binding affinity of O 2 to Hb. OECs were determined with a Hemox Analyzer (TCS Scientific Company) that determines the oxygen partial pressure and degree of HbS saturation with O 2 by means of spectrophotometry and a Clark oxygen electrode, respectively.
Purified Hb (25 µM, tetrameric) samples were incubated in TES/saline buffer (30 mM TES, 130 mM NaCl, 5 mM KCl, pH 7.4 at 25 °C) for 45 min at 37 o C in the absence or presence of test compound. In vitro blood samples (100 µl, 20% Hct, 1 mM Hb,) from transfused sickle cell donors were incubated for 1 hour at 37 o C. In vitro blood samples were then diluted 50-fold, in TES/saline buffer and transferred to the TCS Hemox Analyzer chamber where they were oxygenated with compressed air for 10 min (for purified Hb) or 20 min (for whole blood) and then deoxygenated with compressed nitrogen (N 2 ). 1 During deoxygenation, the p50 values were determined automatically by the Hemox Analytical Software (HAS) [TCS Scientific Company] .
Time dependence of hemoglobin-oxygen affinity. The time dependence of hemoglobin-oxygen affinity was measured using hemoximetry. Purified Hb (25 µM, tetrameric) samples were incubated in hemox buffer (30 mM TES, 130 mM NaCl, 5 mM KCl, pH 7.4 at 25 °C) for 0-130 min at 37 o C in the presence of Compound 1 (5 mM, tested for 0-113 minutes), Compound 4 (100 µM) or Compound 5 (100 µM). Samples were then transferred to the TCS Hemox Analyzer chamber where they were oxygenated with compressed air for 10 min (for purified Hb) and then deoxygenated with compressed nitrogen (N 2 ). During deoxygenation (10 min), the p50 values were determined automatically by the Hemox Analytical Software (HAS) [TCS Scientific Company] .. e.
Polymerization assay HbS polymerization assays were performed as previously described 1 with minor modifications. For all polymerization experiments, 50 µM of HbS in 1.8 M KH 2 PO 4 at pH 7.4 was used. To evaluate the ability of the test compound to delay polymerization, HbS was first incubated with the test compound (prepared from a 100% DMSO stock to the indicated concentrations) for 1 hr at 37 o C. The final DMSO concentration was 0.3%. The Hb solution was deoxygenated in a hypoxic chamber (99.5% N 2 /0.5% O 2 ) for 90 min at 4 o C and polymerization was initiated by increasing the temperature from 4 o C to 37 o C. Polymerization was measured by the increase in absorbance at 700 nm for 50 minutes. A plot of the optical density (at 700 nm) against time was analyzed using the Boltzman sigmoidal fit and the delay time, defined as the time at half Vmax, was determined from the fitted curve. Table 1 a Data expressed as Δp50%: the % change from baseline of pO 2 at which HbS (at 25 M) is 50% saturated with O 2 in the presence of test compound at 30 M; data format: data ± SD dev. Table 2 a Data expressed as Δp50%: the % change from baseline of pO 2 at which HbS (at 25 M) is 50% saturated with O 2 in the presence of test compound at 30 M; data format: data ± SD dev. (v/v) final concentration) to the crystallization condition before flash-freezing in liquid nitrogen. X-ray diffraction data was collected at beamline 8.3.1. at the Advanced Light Source (ALS), Berkeley CA, using a wavelength of 1.11 Å. CO-HbS was co-crystallized with either compound 6 or compound 31 in the P2 1 2 1 2 1 spacegroup with a single HbS tetramer per asymmetric unit. Data reduction was carried out using MOSFLM. 2 All models were built using COOT 3 and further refinement was carried out using the latest builds of the PHENIX suite. 4 The coordinates have been deposited to the Protein Data Bank (PDB codes 5UFJ and 5U3I). Figures were made using PyMOL version 1.6 (Schrodinger, 2016). General method step 1 (Scheme 1) for preparing substituted methylene chloride (1B). To a solution of substituted methylene alcohol (1A) (0.1 to 2 mmol) in DCM (1-10 mL) was added SOCl 2 dropwise (2 to 5 equiv) at 0 o C or rt. The reaction mixture was stirred at rt for 10min to 6 h, or until reaction is judged complete (LC/MS). The reaction mixture is concentrated to dryness over a rotavap.
The crude chloride residue was suspended in toluene, sonicated and concentrated to dryness. The process was repeated three times and dried under vacuum to give the substituted methylene chloride (1B), usually as an off-white solid, which was used for next step without further purification.
Alternatively, a solution of aqueous 1N Na 2 CO 3 is then added to produce a solution of pH~ 8. the mixture was extracted with DCM (3 x10-50mL), dried over sodium sulfate, and concentrated to the crude substituted methylene chloride (1B), which is then purified by column chromatography on silica gel (0-100% ethyl acetate-hexanes).
General method step 2 (Scheme 1) for preparing aryloxy/heteroarylether analogs (1D) from substituted methylene alcohol (1B) and hydroxyl (hetero)aryl aldehyde derivatives (1C). A hydroxyl (hetero)arylaldehyde derivatives (1C) (0.1-2 mmol) mixture with substituted methylene alcohol (2) (0.8 to 1.2equiv) and (polymer-supported)/PPh 3 (1-1.5equiv) in anhydrous THF (1-10mL) was stirred under nitrogen until complete dissolution. The solution was cooled to 0 o C on ice bath and DIAD or DEAD (1.1 equiv) in THF or toluene was added drop wise over a 1-20 min period. The ice cooling bath was allowed to expire over 90 min and the mixture was stirred at rt for 2-48 hours. The mixture was stirred for 10 min, then filtered through a pad of silica. The silica was washed with ethyl acetate 2-20mL. The combined filtrates were evaporated and the residue was dried on highvac. The residue was purified by preparative HPLC or flash silica gel chromatography.
General method step 2 (Scheme 1) for preparing aryloxy/heteroarylether analogs (1D) from substituted methylene halide (1B) and hydroxyl (hetero)aryl aldehyde derivatives (1C). A mixture of hydroxyl (hetero)arylaldehyde derivatives (1C) (0.1-2 mmol, 1-4 equiv), substituted methylene chloride or bromide (1B) (1equiv), and K 2 CO 3 (2-5 equiv) (catalytic amount of NaI or Bu 4 NI may also be added) in DMF, acetonitrile, NMP or DMSO (1 to 10 mL) was stirred at rt or heating up to 120 o C for 1-24 h under nitrogen atmosphere. In workup A, water was added to the reaction mixture, the precipitated product was collected, washed with water, and then subjected to preparative HPLC or flash silica gel chromatography purification. In workup B (for products that did not precipitate), diluted HCl or aqueous NH 4 Cl was added at 0 o C to adjusted the pH to ~7, the reaction mixture was partitioned between ethyl acetate or dichloromethane and aqueous sodium chloride and the organic layer separated, dried, and solvent removed under vacuum to afford crude product which was purified by automated silica gel column chromatography using appropriate solvents mixture (e.g., ethyl acetate/hexanes).
5-hydroxy-2-methoxyisonicotinaldehyde (INT-1).
Step 1. To a mixture of 6-methoxypyridin-3-ol (25 g, 0.2 mol) and K 2 CO 3 (82.8 g, 0.6 mol) in DMF (250 mL) was added bromomethyl methyl ether (30 g, 0.24 mmol) slowly at rt for a period of 1h. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified on silica gel with 25% EtOAc/hexanes eluent to give 2-methoxy-5-(methoxymethoxy)pyridine (20 g, 59%) as a colorless oil.
Step 2: To a solution of 2-methoxy-5-(methoxymethoxy)pyridine (20 g, 0.1 2 mol) in THF was added diisopropylamine (0.24 g, 2.4 mmol). The solution was cooled to -40 o C followed by addition of MeLi (3M/THF, 72mL, 0.216 mol) slowly. The resulting mixture was warmed to 0 o C, stirred at 0 o C for 3 h, cooled back down to -40 o C and added N-formylpiperidine (24mL, 0.216mol). After stirring at -40 o C for 2 h, the mixture was quenched with a mixed solution of HCl (37%, 120 mL) and THF (250 mL).
The temperature was then raised to rt and diluted with water (200 mL) and EtOAc (200 mL). The pH of the mixture was adjusted to 8-9 with solid K 2 CO 3 and extracted with EtOAc (300 mL) twice. The organic layer was combined, dried over Na 2 SO 4 , and concentrated. The residue was purified on silica gel with 25%EtOAc/hexanes as eluent to give 2-methoxy-5-(methoxymethoxy)isonicotinaldehyde ( Step 3: To a solution of 2-methoxy-5-(methoxymethoxy)isonicotinaldehyde (10 g, 0.05 mol) in THF (100 mL) was added 3 N HCl (150 mL). The reaction was stirred at 50 o C for 30 min, cooled to rt, and diluted with water (100 mL). The mixture was neutralized to pH 7-8 and extracted with EtOAc (200 mL) three times. The organic layer was dried over Na 2 SO 4 and concentrated to give 5-hydroxy-2methoxyisonicotinaldehyde (4. Step1. To a solution of 2-bromonicotinic acid (4.0 g, 20 mmol) and triethylamine (3.34 mL, 24 mmol, 1.2 equiv) in THF (100 mL) was added i-butyl chloroformate (3.12 mL, 24 mmol, 1.2 eq.) at 0 o C. The mixture was stirred at 0 o C for 10 min and filtered. To this filtrate was added a suspension of NaBH 4 (1.52 g, 40 mmol, 2 equiv) in water (1.0 mL) at 0 o C. The mixture was stirred for 30 min, added water (3 mL), continued to stir for 2 h, and concentrated to dryness. The crude was purified on silica gel using a mixture of ethylacetate and hexanes as eluent to give (2- Step2. To (2-bromopyridin-3-yl)methanol (380 mg, 2 mmol) in DCM ( 5 mL) was added SOCl 2 (1 mL) at rt. The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give an off-white solid (INT-3) (480 mg), which was used for next step without further purification.
Step 3. A mixture of 5-hydroxy-2-methoxyisonicotinaldehyde (306 mg, 2 mmol, 1 equiv), 2-bromo-3-(chloromethyl)pyridine (crude above, 2 mmol), and K 2 CO 3 (828 mg, 6 mmol, 3 equiv) in DMF (1.0 mL) was heated at 50 o C for 2 h. The mixture was cooled and added to water (50 mL) dropwise. The precipitate was filtered, washed with water, dried under high vacuo to give 5-( (2- Step1. To a 500-mL flask containing the pyrazole boronate (9.0g, 38.1mmol), 2-chloropyridine (5.47g, 38.1mmol) , Pd(dppf)Cl 2 ([1,1-bis(diphenylphosphino) Step2. To a solution of (2-
in DCM (4 mL 
5-(Imidazo[1,2-a]pyridin-8-ylmethoxy)-2-methoxyisonicotinaldehyde (6).
The title compound was prepared from INT-1 and 8-(chloromethyl)imidazo [1,2-a] 
5-(Benzo[d]oxazol-4-ylmethoxy)-2-methoxyisonicotinaldehyde (9).
The 
8-(((4-Formyl-6-methoxypyridin-3-yl)oxy)methyl)imidazo[1,2-a]pyridine-6-carbonitrile (11).
A mixture of 5-((6-bromoimidazo [1,2-a] 
.
5-(Imidazo[1,5-a]pyridin-8-ylmethoxy)-2-methoxyisonicotinaldehyde (12).
The title compound was prepared from INT-1 and 8-(chloromethyl)imidazo [1,5-a] 
5-((6-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-8-yl)methoxy)-2-methoxyisonicotinaldehyde (21).
A mixture of 8-(((4-formyl-6-methoxypyridin-3-yl)oxy)methyl)imidazo [1,2-a] 
5-((6-(1H-pyrazol-5-yl)imidazo[1,2-a]pyridin-8-yl)methoxy)-2-methoxyisonicotinaldehyde (22).
Step 1 
5-((6-(1H-pyrazol-5-yl)imidazo[1,2-a]pyridin-2-yl)methoxy)-2-methoxyisonicotinaldehyde (23).
Step 1. To a solution of (7-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)imidazo [1,5a] pyridin-8-yl)methanol (46 mg, 0.133 mmol) in THF (10 mL) was added TEA (117 µL, 0.6 mmol) and
MsCl (37 µL, 0.48 mmol). The mixture was stirred at ambient temperature until completion. It was diluted with water and extracted with EtOAc . The crude product was used directly for Step 2 without purification.
Step 2. To a solution of above crude product in DMF (5 mL) was added INT-1 (60 mg, 0.4 mmol) and K 2 CO 3 (73 mg, 0.53 mmol). The mixture was heated at 70 °C for 2 h. It was filtered and the filtrate was concentrated. The crude product was purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 2-methoxy-5-((7-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-5-yl)imidazo [1,5a] pyridin-8-yl)methoxy)isonicotinaldehyde (21 mg, 33% yield).
Step 3. To a solution of SEM protected intermediate (21 mg, 0.044 mmol) in EtOH (2 mL 
5-((2-(1H-pyrazol-5-yl)quinolin-4-yl)methoxy)-2-methoxyisonicotinaldehyde (24).
The title compound was prepared using similar procedures as these for 22, starting from 5-( (2 (2-(1H-pyrazol-5-yl) pyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (25).
5-(
Step 1: 5-( (2- Step 2 
5-((5-(1H-pyrazol-5-yl)pyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (26).
Step 1. 005-59 was prepared from INT-1 and 3-bromo-5-(chloromethyl)pyridine according to the general procedure step 2 to give the product as an off-white solid in 63% yield. Step 2. The title compound was prepared using similar procedures as these for 20, starting from 5-( (2-bromopyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde and tert-butyl 5- (4,4,5,5-tetramethyl-1,3,2- 
2-methoxy-5-((5-(1-methyl-1H-pyrazol-3-yl)pyridin-3-yl)methoxy)isonicotinaldehyde (27).
The title compound was prepared using similar procedures as these for 20, step1 (Suzuki coupling), 5-((2-(1-methyl-1H-pyrazol-5-yl) pyridin-3-yl)methoxy)isonicotinaldehyde (28).
2-methoxy-
Step1. To a mixture of (2-bromopyridin-3-yl) Step 2 Step 5. To (E)-1- (3-((tert-butyldimethylsilyloxy) methyl)pyridin-2-yl)-3-(dimethylamino)prop-2-en-1one (crude above, 966.4 mg, 3.02 mmol, 1 eq.) in EtOH (10 mL) was added methylhydrazine (1.0 mL) at rt. The mixture was heated at 80 o C for 2 h, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give a mixture of regio-isomers (420 mg; 46% for 2 steps). MS (ESI) m/z 304.2 [M+H] + .
Step 6. To a mixture of 3-((tert-butyldimethylsilyloxy)methyl)-2-(1-methyl-1H-pyrazol-5-yl)pyridine and 3-((tert-butyldimethylsilyloxy)methyl)-2-(1-methyl-1H-pyrazol-3-yl)pyridine (420 mg, 1.38 mmol) in MeOH (20 mL) was added HCl (4 N, 2.0 mL). The mixture was stirred at rt for 1 h, concentrated, and diluted with EtOAc (50 mL) and NaHCO 3 (sat) solution (10 mL). The layers were separated and aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na 2 SO 4 , concentrated, and purified on silica gel using EtOAc as eluent to give (2-(1-methyl-1Hpyrazol-5-yl)pyridin-3-yl)methanol (187 mg, 72%) and (2- Step 7. To (2-(1-methyl-1H-pyrazol-5-yl)pyridin-3-yl)methanol (182 mg, 0.96 mmol) in DCM (5 mL) was added SOCl 2 (1.5 mL) at rt. The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3-(chloromethyl)-2-(1-methyl-1H-pyrazol-5yl)pyridine (236 mg) as an off-white solid, which was used for next step without further purification. Step 8. A mixture of 5-hydroxy-2-methoxyisonicotinaldehyde (147 mg, 0.96 mmol, 1 eq.), 3-(chloromethyl)-2-(1-methyl-1H-pyrazol-5-yl)pyridine hydrochloride (236 mg, 0.96 mmol, 1 equiv), and 5-((2-(4-methyl-1H-pyrazol-5-yl) pyridin-3-yl)methoxy)isonicotinaldehyde (29).
MS (ESI

2-methoxy-
Step 1. To a mixture of 5-( (2- Step 2. To 2-methoxy-5-((2-(4-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyridin-3yl)methoxy)isonicotinaldehyde (110 mg, 0.27 mmol, 1 equiv) suspended in EtOH (1 mL) was added HCl (1.0 mL, 3 N) . The solution turned homogeneous and the mixture was stirred at rt overnight. The EtOH was partially removed by blowing in N 2 gas and basified to pH 9. The aqueous solution was extracted with EtOAc three times. The organic layer was dried over Na 2 SO 4 and concentrated. The crude was purified on silica gel using a mixture of MeOH and DCM as eluent to give 2-methoxy-5-( (2-(4-methyl-1H-pyrazol-5-yl) 3.98 (s, 3 H) . 2-(1,4-dimethyl-1H -pyrazol-5-yl)pyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (30).
5-((
The title compound was prepared using similar procedures as these for 20, step1 (Suzuki coupling), starting from 5-((2-bromopyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (INT4) and 1,4dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, the product was obtained as a light yellow oil in 82% yield. MS (ESI) m/z 339.2 [M+H] + ; 1 H NMR (400 MHz, Chloroform-d) δ 10.38 (s, 1H), 8.78 (dd, J = 4.8, 1.7 Hz, 1H), 8.08 (dt, J = 8.0, 1.1 Hz, 1H), 7.82 (s, 1H), 7.49 (dd, J = 7.9, 4.8 Hz, 1H), 1H) , 7.08 (d, J = 0.6 Hz, 1H), 5.04 (d, J = 13.7 Hz, 2H), 3.90 (s, 3H), 3.72 (s, 3H), 1.96 (s, 3H) .
5-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (31).
Step 1. To (E)-1- (3-((tert-butyldimethylsilyloxy) methyl)pyridin-2-yl) -3-(dimethylamino) prop-2-en-1one (crude, 1.03 g, 3.22 mmol, 1 eq.; refer to Example 28, step 4) in EtOH (10 mL) was added isopropylhydrazine hydrochloride (430 mg, 3.86 mmol, 1.2 eq.). The mixture was heated at 80 o C for 2 h, cooled, added HCl (6 N, 0.5 mL), and stirred overnight. The mixture was concentrated and diluted with EtOAc (80 mL) and NaHCO 3 (sat) (10 mL) solution. The layers were separated and the aqueous layer was extracted with EtOAc three times. The combined organic layers were dried over Na 2 SO 4,  concentrated, and purified on silica gel using EtOAc as eluent to give ( Step 2. To (2-(1-iospropyl-1H-pyrazol-5-yl) pyridin-3-yl)methanol (560 mg, 2.58 mmol) in DCM ( 10 mL) was added SOCl 2 (3.0 mL) at rt. The reaction mixture was stirred at rt for 4 h and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5yl)pyridine hydrochloride (700 mg) as an off-white solid, which was used for next step without further purification.
Step 3. A mixture of 5-hydroxy-2-methoxyisonicotinaldehyde (395 mg, 2.58 mmol, 1 eq.), 3-(chloromethyl)-2-(1-isopropyl-1H-pyrazol-5-yl)pyridine hydrochloride (700 mg, 2.58 mmol, 1 equiv), and K 2 CO 3 (1.4 g, 10.32 mmol, 4 equiv) in DMF (10.0 mL) was heated at 70 o C for 2 h. The mixture was cooled, filtered, concentrated, and purified on silica gel using a mixture of EtOAc and hexanes as eluent to give 5-( (2-(1-isopropyl-1H-pyrazol-5-yl) 68 , 159.71 , 149.69 , 149.49 , 149.26 , 138.37 , 137.85 , 136.87 , 133.85 , 133.03 , 131.26 , 123.55 , 108.80 , 107.12 , 68.68 , 54.12 , 51.01 , 22.97 .
5-((5-(1H-pyrazol-4-yl)pyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (32).
The title compound was prepared using similar procedures as these for 20, starting from 5-((4bromopyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde and tert-butyl 4- (4,4,5,5-tetramethyl-1,3,2- 
5-((5-(2H-tetrazol-5-yl)pyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (33).
The title compound was prepared using similar procedures as these for 21, starting from 5-((5bromopyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde, the product was obtained as a white solid ((2-(1H-pyrazol-1-yl)pyridin-3-yl) (1-(2-hydroxyethyl) -1H-pyrazol-5-yl)pyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (35).
5-
5-((2-
Step 1. To a solution of 2-(1H-pyrazol-1-yl)ethan-1-ol (250 mg, 2.23 mmol) in THF (7.5 mL) at 0 °C was added TMEDA (670 µL, 4.46 mmol) and BuLi (2.5 M, 2 mL, 5 mmol) dropwise. The mixture was stirred at 0 °C for 30 min. The mixture was added triisopropylborate (620 µL, 2.68 mmol). Ice bath was removed and the reaction mixture was warmed up to ambient temperature. After stirred for additional 3 h, the reaction mixture was quenched with MeOH. After removal of rganic solvents, the crude product was used directly for Step 2 without purification.
Step 2. To a solution of above crude product in dioxane (6 mL) was added 5-( (2- 6-((2-(1-isopropyl-1H-pyrazol-5-yl) pyridin-3-yl)methoxy)benzaldehyde (36).
2-Hydroxy-
Step a. To a solution of 2-bromobenzene-1,3-diol (47) Step b. To a solution of 2-bromo-1,3-bis(methoxymethoxy)benzene (48) Step c. To a solution of 2,6-bis(methoxymethoxy)benzaldehyde (49) Step e. To a solution of (2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methanol) (53, INT-5) (440mg, 2.02mmol) in DCM (4 mL) was added SOCl 2 (2eq) at 0 o C. The reaction mixture was stirred at rt for 15mins and concentrated to dryness. The crude solid was suspended in toluene and concentrated to dryness. The process was repeated three times and dried under vacuum to give 3-(chloromethyl)-2-(1-
To 5-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)-2-methoxyisonicotinaldehyde (31) (400 mg, 1.135 mmol) in a vial was added HCl (12 N, 1 mL). The reaction was heated in a microwave reactor at 125 o C for 45 min. The mixture was concentrated and dried, and dissolved in NaOH (3 N, 5 mL), filtered, and washed with with EtOAc twice. The pH of the aqueous layer was adjust to pH 6-7, filtered, and purified by RP-HPLC (Gemini 21.2 x 150 mm) with a mixture of CH 3 CN and water (0.1% HCOOH) as eluent to give the product (100 mg, 26%) as an yellow solid. HRMS calcd for C 18 H 19 N The title compound was prepared according to the procedure in Example 62.
To 5-(imidazo [1,2-a] pyridin-8-ylmethoxy)-2-oxo-1,2-dihydropyridine-4-carbaldehyde (37) (100 mg, 0.295 mmol, 1 equiv) in CH 3 CN (10 mL) was added sodium 2-chloro-2,2-difluoroacetate (84.5 mg, 0.56 mmol, 1.5 eq.). The mixture was stirred at rt overnight and concentrated. The crude was purified on silica gel using 10% MeOH/DCM as eluent to give 2-(difluoromethoxy)-5-(imidazo [1,2-a] 
5-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)-2-(2methoxyethoxy)isonicotinaldehyde (39).
To a mixture of 5-(imidazo [1,2-a] pyridin-8-ylmethoxy)-2-oxo-1,2-dihydropyridine-4-carbaldehyde (100 mg, 0.295 mmol, 1 equiv) and K 2 CO 3 (153.2 mg, 1.11, 3.0 eq.) in DMF (5 mL) was added 1bromo-2-methoxyethane (154.3 mg, 1.11 mmol, 3.0 eq.). The mixture was stirred at rt overnight, filtered, concentrated, and purified on silica gel using 10% MeOH/DCM as eluent to give 5-(imidazo [1,2-a] 
